Amended FDA Protocol Submitted for Phase 2b Trial of Advanced Alzheimer’s Therapy

Amended FDA Protocol Submitted for Phase 2b Trial of Advanced Alzheimer’s Therapy
Neurotrope BioScience has submitted an amended protocol to the U.S. Food and Drug Administration (FDA) for a Phase 2b clinical trial of its lead product candidate bryostatin-1 for treating advanced Alzheimer’s disease. The company said in a press release that in the original trial protocol, the primary efficacy outcome is at week 13, unchanged with this amendment,

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *